FY2023 · ended Dec 31, 2023 · Revenue $2.38M, +46.6% YoY · Filed Apr 1, 2024
Panacea Life Sciences Holdings, Inc. (PLSH) files with the SEC under industry code 2833, Medicinal Chemicals & Botanical Products. In fiscal 2023, which ended Dec 31, 2023, it reported revenue of $2.4 million and a net loss of $8.0 million. Free cash flow was -$1.6 million. As of Mar 31, 2024 it held $117,147 in cash and investments and $3.8 million in total debt.
Revenue (TTM)
$2.76M
+50.4% vs year-ago TTM
Net income (TTM)
$-7.67M
+5.9% vs year-ago TTM
Operating cash flow (TTM)
$-1.57M
+31.2% vs year-ago TTM
Free cash flow (TTM)
$-1.62M
+35.8% vs year-ago TTM
EPS
$-0.48
Dividend per share
None
Shares outstanding
17.65M
+19.5% vs prior year
Net cash
$-3.68M
as of Mar 31, 2024
Operating margin
-192.2%
FY 2024
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- PLSH (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Greenwood Village, CO
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1552189
- Former names
- Exactus, Inc. (until Oct 26, 2021); Spiral Energy Tech., Inc. (until Mar 4, 2016); Solid Solar Energy, Inc. (until Aug 7, 2013)
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
FY 2020 Dec 31, 2020 |
FY 2019 Dec 31, 2019 |
|---|---|---|---|---|---|
| Revenue | $2.4M | $1.6M | $2.1M | $9.0M | $345,680 |
| Operating income | -$5.5M | -$5.7M | -$5.9M | -$5.3M | -$10.7M |
| Net income | -$8.0M | -$9.1M | -$4.8M | -$5.2M | -$10.0M |
| Diluted EPS | -$0.48 | — | — | — | — |
| Operating cash flow | -$1.5M | -$2.4M | -$3.9M | -$7.6M | -$5.7M |
| Free cash flow | -$1.6M | -$2.6M | -$4.1M | -$10.8M | -$6.3M |
| Total assets | $18.0M | $19.5M | $23.8M | $31.4M | $8.0M |
| Total liabilities | $26.3M | $21.6M | $16.7M | $24.7M | $4.1M |
| Stockholders' equity | -$8.3M | -$2.1M | $7.1M | $6.7M | $11.9M |
| Cash and investments | $115,855 | $1.1M | $3.8M | $84,379 | $18,405 |
| Total debt | $4.0M | $3.3M | $3.7M | $965,401 | $576,717 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Other events
|
May 16, 2024 | May 13, 2024 |
| 8-K |
Current report
Auditor change
|
May 7, 2024 | May 3, 2024 |
| 10-Q | Quarterly report | May 6, 2024 | Mar 31, 2024 |
| 10-K | Annual report | Apr 1, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Material agreement, New debt
|
Mar 7, 2024 | Mar 5, 2024 |
| 8-K |
Current report
Material agreement
|
Feb 5, 2024 | Jan 29, 2024 |
All 316 Panacea Life Sciences Holdings, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.